

MOBERG PHARMA AB

- ✓ Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds.
- ✓ Initially, the company is specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.
- ✓ The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with ongoing phase 3 studies covering more than 800 patients.
- ✓ The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis.
- ✓ Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches.
- ✓ Moberg Pharma is headquartered in Stockholm and is listed on Nasdaq Stockholm (OMX: MOB).

- **OCAPI of SEK 216M / 36 months**
- **Turnover 2019: SEK 281 M**
- **Market capitalization: SEK 260 M**

